Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2012
11/20/2012US8313912 Cancer specific oligosaccharide sequences and use thereof
11/20/2012CA2716894C A magnetic breather pump and a method for treating a brain tumor using the same
11/20/2012CA2692358C Recombinant human interferon-like proteins
11/20/2012CA2633171C Antibodies against tumor-associated antigenic target (tat) polypeptides
11/20/2012CA2583699C Stat3 phosphorylation inhibitor and notch1 expression inhibitor
11/20/2012CA2560278C Modified bouganin proteins, cytotoxins and methods and uses thereof
11/20/2012CA2490735C Liquid preparation comprising oligopeptides and etherified cyclodextrin
11/20/2012CA2482929C Tuberculin immunoadjuvant
11/20/2012CA2482687C Treatment of mesothelioma
11/20/2012CA2421580C Discrimination between gnrh-i and gnrh-ii
11/20/2012CA2380331C Multiple cytokine-antibody complexes
11/15/2012WO2012155108A1 Treatments for disorders using guanylate cyclase c agonists
11/15/2012WO2012155101A1 Treatments for gastrointestinal disorders
11/15/2012WO2012155066A2 Spiro-oxindole mdm2 antagonists
11/15/2012WO2012154988A2 Fiduciary markers and methods of placement
11/15/2012WO2012154975A2 Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion
11/15/2012WO2012154942A2 Ceramide anionic liposome compositions
11/15/2012WO2012154885A2 Carbonic anhydrase targeting agents and methods of using same
11/15/2012WO2012154861A2 Cancer treatments
11/15/2012WO2012154799A1 Herbal composition for treating cancer
11/15/2012WO2012154759A2 Genetically engineered growth factor variants
11/15/2012WO2012154587A2 Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
11/15/2012WO2012154194A1 Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
11/15/2012WO2012154126A1 A slow-releasing hydrogen sulphide donor in a method for the treatment of cancer
11/15/2012WO2012153775A1 Thioxothiazolidine derivative having ras function inhibitory effect
11/15/2012WO2012153707A1 Antibody specifically recognising transferrin receptor
11/15/2012WO2012153620A1 Drug, functional food, method for stabilizing target protein, fused protein, nucleic acid, and recombinant
11/15/2012WO2012153493A1 Photodynamic therapy or diagnostic agent, using infrared-spectrum light
11/15/2012WO2012153492A1 Nptx2 as tumor marker and therapeutic target for cancer
11/15/2012WO2012153193A2 Protein-active agent conjugates and method for preparing the same
11/15/2012WO2012152918A1 Semuloparin for the prevention of venous thromboembolism in cancer patients receiving chemotherapy
11/15/2012WO2012152885A1 Combination of a statin and a taxane for the treatment of gastric cancer
11/15/2012WO2012152763A1 Substituted indazole derivatives active as kinase inhibitors
11/15/2012WO2012152209A1 4-carboxy phenyl retinamidethanolate, preparation method and pharmaceutical composition thereof
11/15/2012WO2012152208A1 Thiazole compound and preparation method and use thereof
11/15/2012WO2012152063A1 Novel biomarker of hcc, rarres2
11/15/2012WO2012129394A9 Methods and compositions for the treatment of cancer
11/15/2012WO2012125981A3 Raf kinase inhibitors
11/15/2012WO2012125693A3 Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same
11/15/2012WO2012122106A3 Compositions and methods apc, creb, and bad pathways to assess and affect cancer
11/15/2012WO2012078831A3 Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity
11/15/2012WO2012078586A9 Pharmaceutical composition comprising nanog shrna, and method of usnig nanog shrna to treat cancer
11/15/2012US20120289932 Device and method for combining a treatment agent and a gel
11/15/2012US20120289760 Cytomegalovirus-based immunogenic preparations
11/15/2012US20120289614 Functionalized biodegradable triclosan monomers and oligomers for controlled release
11/15/2012US20120289605 Method for inducing udp-glucuronosyltransferase activity using pterostilbene
11/15/2012US20120289592 Ercc1 gene expression level is associated with clinical outcomes in esophageal cancer patients
11/15/2012US20120289584 Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
11/15/2012US20120289583 Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
11/15/2012US20120289581 Diagnostic, prognostic and therapeutic uses of long non-coding rnas for cancer and regenerative medicine
11/15/2012US20120289576 Process for Forming Amorphous Atorvastatin
11/15/2012US20120289571 Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
11/15/2012US20120289570 Compositions and methods for treating and/or preventing cancer by inhibiting fatty acid binding proteins
11/15/2012US20120289569 Inhibitors of ubiquitin e1
11/15/2012US20120289552 Aryl ureas with angiogenesis inhibiting activity
11/15/2012US20120289545 Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof
11/15/2012US20120289540 Kinase inhibitors useful for the treatment of proliferative diseases
11/15/2012US20120289536 Pharmaceutical Compositions Comprising Colloidal Silicon Dioxide
11/15/2012US20120289533 Use of Manzamine Compounds in Anti-Cancer Therapeutic Regimens
11/15/2012US20120289528 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
11/15/2012US20120289527 Mono-hydrochloric salts of an inhibitor of histone deacetylase
11/15/2012US20120289518 Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
11/15/2012US20120289510 Benzyl Amines, A Process For Their Production And Their Use As Anti-Inflammtory Agents
11/15/2012US20120289509 Heterocyclic compound as protein kinase inhibitor
11/15/2012US20120289507 Organic compounds as smo inhibitors
11/15/2012US20120289501 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
11/15/2012US20120289499 Process
11/15/2012US20120289498 Compositions And Methods Relating To Novel Compounds And Targets Thereof
11/15/2012US20120289496 Novel compounds as modulators of protein kinases
11/15/2012US20120289494 Spiro-oxindole mdm2 antagonists
11/15/2012US20120289484 Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
11/15/2012US20120289483 Compounds for the treatment of proliferative disorders
11/15/2012US20120289481 Compositions and methods for treating cancer
11/15/2012US20120289480 Cyclodextrin-based polymers for therapeutics delivery
11/15/2012US20120289475 Certain Compounds, Compositions and Methods
11/15/2012US20120289452 Compositions and methods for treating and preventing necrosis
11/15/2012US20120288931 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
11/15/2012US20120288876 Novel identified oncogene with kinase-domain (nok)
11/15/2012US20120288558 Method for administration of pegylated liposomal doxorubicin
11/15/2012US20120288557 Acoustically sensitive drug delivery particles comprising low concentrations of phosphatidylethanolamine
11/15/2012US20120288556 Ceramide anionic liposome compositions
11/15/2012US20120288555 Antiproliferative compositions comprising curcumin analogs and methods of producing and using same
11/15/2012US20120288554 Canfosfamide monotherapy for treating multiple myeloma
11/15/2012US20120288541 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
11/15/2012US20120288538 Vaccine against neoplastic or cancerous lesions caused by human papilloma virus (hpv), procedures, uses and methods
11/15/2012US20120288537 Active self-healing biomaterial system
11/15/2012US20120288536 Stabilized Stat3 Decoy Oligonucleotides And Uses Therefor
11/15/2012US20120288532 Multi-layered, multiple unit pharmaceutical compositions
11/15/2012US20120288528 Mono-and disaccharide derivatives
11/15/2012US20120288516 Markers of XMRV Infection And Uses Thereof
11/15/2012US20120288515 Synthetic long peptide (slp)-based vaccines
11/15/2012US20120288514 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
11/15/2012US20120288509 Analysis of methylated nucleic acid
11/15/2012US20120288506 C-kit antibodies and uses thereof
11/15/2012US20120288504 Antagonists of il-6 to prevent or treat thrombosis
11/15/2012US20120288501 Substituted benzazoles and methods of their use as inhibitors of raf kinase
11/15/2012US20120288500 Human monoclonal antibodies to btla and methods of use
11/15/2012US20120288499 Methods for diagnosis and treatment of cutaneous t cell lymphomas
11/15/2012US20120288498 Polynucleotides and polypeptide sequences involved in cancer
11/15/2012US20120288497 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
1 ... 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 ... 2211